60 related articles for article (PubMed ID: 15650365)
21. Short communication: CD4 cell count increases during successful treatment of Graves' disease with methimazole in HIV-infected patients on antiretroviral therapy.
Honda A; Kashiwazaki K; Tsunoda T; Gallant JE; Brown TT
AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1627-9. PubMed ID: 22632156
[TBL] [Abstract][Full Text] [Related]
22. Effects of recombinant human interleukin-2 and tumor necrosis factor-alpha with or without interferon-gamma on human thyroid tissues from patients with Graves' disease and from normal subjects xenografted into nude mice.
Kasuga Y; Matsubayashi S; Akasu F; Miller N; Jamieson C; Volpé R
J Clin Endocrinol Metab; 1991 Jun; 72(6):1296-301. PubMed ID: 1902846
[TBL] [Abstract][Full Text] [Related]
23. Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents.
Wood LC; Ingbar SH
J Clin Invest; 1979 Nov; 64(5):1429-36. PubMed ID: 91625
[TBL] [Abstract][Full Text] [Related]
24. Persistent remission of Graves` disease or evolution from Graves' disease to Hashimoto's thyroiditis in childhood - a report of 6 cases and clinical implications.
Smyczńyska J; Cyniak-Magierska A; Stasiak M; Karbownik-Lewińska M; Lewiński A
Neuro Endocrinol Lett; 2014; 35(5):335-41. PubMed ID: 25275265
[TBL] [Abstract][Full Text] [Related]
25. Thyrotropin binding inhibiting immunoglobulins (TBII) in Graves' disease, toxic nodular goitre and autoimmune thyroiditis.
Wägar G; Mäkinen T; Lamberg BA; Gordin A; Apter L; Pekonen F
Ann Clin Res; 1982 Apr; 14(2):83-9. PubMed ID: 6184007
[TBL] [Abstract][Full Text] [Related]
26. A change from stimulatory to blocking antibody activity in Graves' disease during pregnancy.
Kung AW; Jones BM
J Clin Endocrinol Metab; 1998 Feb; 83(2):514-8. PubMed ID: 9467567
[TBL] [Abstract][Full Text] [Related]
27. Different immunophenotype and autoantibody production by peripheral blood and thyroid-derived lymphocytes in patients with Graves' disease.
Aust G; Lehmann I; Heberling HJ
Exp Clin Endocrinol Diabetes; 1996; 104(1):50-8. PubMed ID: 8750571
[TBL] [Abstract][Full Text] [Related]
28. Thyroid diseases after treatment of Hodgkin's disease.
Hancock SL; Cox RS; McDougall IR
N Engl J Med; 1991 Aug; 325(9):599-605. PubMed ID: 1861693
[TBL] [Abstract][Full Text] [Related]
29. Increase of serum interleukin-10 in intractable Graves' disease.
Takeoka K; Watanabe M; Matsuzuka F; Miyauchi A; Iwatani Y
Thyroid; 2004 Mar; 14(3):201-5. PubMed ID: 15072702
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy.
Kovacs JA; Vogel S; Metcalf JA; Baseler M; Stevens R; Adelsberger J; Lempicki R; Hengel RL; Sereti I; Lambert L; Dewar RL; Davey RT; Walker RE; Falloon J; Polis MA; Masur H; Lane HC
Eur J Immunol; 2001 May; 31(5):1351-60. PubMed ID: 11465092
[TBL] [Abstract][Full Text] [Related]
31. Decrease of immunoglobulin G-Fc receptor-bearing T lymphocytes in Graves' disease.
Mori H; Amino N; Iwatani Y; Asari S; Izumiguchi Y; Kumahara Y; Miyai K
J Clin Endocrinol Metab; 1982 Sep; 55(3):399-402. PubMed ID: 6178751
[TBL] [Abstract][Full Text] [Related]
32. Stress and autoimmune thyroid diseases.
Bagnasco M; Bossert I; Pesce G
Neuroimmunomodulation; 2006; 13(5-6):309-17. PubMed ID: 17709953
[TBL] [Abstract][Full Text] [Related]
33. 2019 European Thyroid Association Guidelines on the Management of Thyroid Dysfunction following Immune Reconstitution Therapy.
Muller I; Moran C; Lecumberri B; Decallonne B; Robertson N; Jones J; Dayan CM
Eur Thyroid J; 2019 Jul; 8(4):173-185. PubMed ID: 31602359
[TBL] [Abstract][Full Text] [Related]
34. CHARACTERISTICS OF GRAVES DISEASE IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY.
Jariyawattanarat V; Sungkanuparph S; Sriphrapradang C
Endocr Pract; 2020 Jun; 26(6):612-618. PubMed ID: 31968184
[No Abstract] [Full Text] [Related]
35. New-onset type 1 diabetes and Graves' disease after antiretroviral therapy in a patient with human immunodeficiency virus infection.
Taguchi M; Ihana-Sugiyama N; Shiojiri D; Izumi K; Kobayashi M; Kodani N; Bouchi R; Ohsugi M; Tanabe A; Ueki K; Kajio H
J Diabetes Investig; 2023 Mar; 14(3):489-493. PubMed ID: 36625362
[TBL] [Abstract][Full Text] [Related]
36. Vitiligo and Graves' disease following treatment of malignant melanoma with recombinant human interleukin 4.
Weiss GR; Fehrenkamp SH; Tokaz LK; Sunderland MC
Dermatology; 1996; 192(3):283-5. PubMed ID: 8726651
[TBL] [Abstract][Full Text] [Related]
37. Response To: Graves Disease in Hiv-Infected Patients.
Sriphrapradang C
Endocr Pract; 2020 Oct; 26(10):1228-1229. PubMed ID: 33471724
[No Abstract] [Full Text] [Related]
38. Graves Disease in Hiv-Infected Patients.
Modarressi T
Endocr Pract; 2020 Oct; 26(10):1227. PubMed ID: 33471723
[No Abstract] [Full Text] [Related]
39. Hyperthyroidism with papillary thyroid carcinoma in HIV: Case report and literature review.
Guan YY
Heliyon; 2023 Mar; 9(3):e14377. PubMed ID: 36967896
[TBL] [Abstract][Full Text] [Related]
40. Kaleidoscope of autoimmune diseases in HIV infection.
Roszkiewicz J; Smolewska E
Rheumatol Int; 2016 Nov; 36(11):1481-1491. PubMed ID: 27544391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
